Micro-cap Active runners: CytRx Corporation (NASDAQ:CYTR), Response Genetics (NASDAQ:RGDX), Catalyst Pharmaceutical Partners (NASDAQ:CPRX), Rexahn Pharmaceuticals (NYSEMKT:RNN)

CytRx Corporation (NASDAQ:CYTR) seeks to present the detailed results of the positive outcome from the study which was conducted in an animal representation of glioblastoma at the AACRAM which will be held from between April 5 and April 9 in San Diego, CA. CytRx Corporation (NASDAQ:CYTR) stock performance was 3.67% in last session and finished the day at $3.95. Traded volume was 11.77million shares in the last session and the average volume of the stock remained 2.85million shares. The beta of the stock remained 1.55. CytRx Corporation (NASDAQ:CYTR) insider ownership is 8.50%.

Headquartered in Los Angeles, California, Response Genetics, Inc. (NASDAQ:RGDX) focuses on developing and selling diagnostics tests that determine a patient’s response to cancer treatments. The company’s new agreements include more Blue Cross Blue Shield deals in West Virginia, Delaware, Pennsylvania, South Dakota, Iowa and Arizona. Response Genetics, Inc. (NASDAQ:RGDX) rose 18.33 percent to $1.42 Thursday on volume of 9.83million shares. The intra-day range of the stock was $1.34 to $1.56. Response Genetics, Inc. (NASDAQ:RGDX) has a market capitalization of $48.63million.

Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases today reported financial results for the fourth quarter and year-ended December 31, 2013. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)’s stock on Apr 03, 2014 reported a increase of 8.60% to the closing price of $2.40. Its fifty two weeks range is $0.45 -$3.65. The total market capitalization recorded $129.95million. The overall volume in the last trading session was million shares. In its share capital, CPRX has 54.14million outstanding shares.

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it will have two poster presentations at the 2014 American Association for Cancer Research (AACR) Annual Meeting. On Thursday, shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) dropped -3.12% to close the day at $1.24. Company monthly performance is recorded as -15.07%. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) quarterly revenue growth is 188.37%.